Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

GPCR Desensitization

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Platelets and Alzheimer Disease: A Link Worth Exploring.

Neurology·2025

Same author

The platelet-mitochondria nexus in autoimmune and musculoskeletal diseases.

Clinical immunology (Orlando, Fla.)·2024

Same author

Heart Failure with Preserved Left Ventricular Ejection Fraction: A Complex Conundrum Simply Not Limited to Diastolic Dysfunction.

Cardiovascular therapeutics·2023

Same author

Time to revisit the true role of metformin in type 2 diabetes mellitus.

Postgraduate medicine·2023

Same author

Growth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management.

Current heart failure reports·2023

Same author

In search of mechanisms to explain the unquestionable benefit derived from sodium-glucose cotransporter-2 (SGLT-2) inhibitors use in heart failure patients.

Postgraduate medicine·2023

Search research articles

Related Experiment Video

Updated: Jun 30, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Cangrelor attenuates coated-platelet formation.

Nicholas B Norgard¹, Callie L Hann, George L Dale

¹Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

|September 18, 2008

Summary

This summary is machine-generated.

Cangrelor, a P2Y12 inhibitor, effectively reduces the production of coated-platelets, which are activated by collagen, thrombin, and adenosine diphosphate (ADP). This study reveals a novel mechanism beyond its anti-aggregation effects.

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Related Experiment Videos

Last Updated: Jun 30, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Area of Science:

Pharmacology
Hematology
Biochemistry

Background:

P2Y12 inhibitors block adenosine diphosphate (ADP)-mediated platelet activation.
Cangrelor is an active, non-metabolized P2Y12 inhibitor.
Coated-platelets support prothrombinase activity and are generated by collagen and thrombin.

Purpose of the Study:

To investigate if P2Y12 inhibitors, specifically cangrelor, can attenuate the potentiation of coated-platelet production by ADP.
To explore a novel role of ADP in enhancing coated-platelet generation.

Main Methods:

In vitro study using cangrelor at physiologically relevant concentrations.
Assessed the effect of cangrelor on ADP-potentiated coated-platelet production.
Measured P-selectin expression to evaluate thrombin-dependent platelet activation.

Main Results:

Cangrelor significantly reduced ADP-dependent coated-platelet production with an IC50 of 1.4 nM.
Cangrelor did not affect thrombin-induced P-selectin expression, indicating no impact on thrombin-dependent activation.
ADP was found to potentiate coated-platelet production by collagen and thrombin.

Conclusions:

Cangrelor exhibits an unexpected action by attenuating ADP-potentiated coated-platelet generation.
This finding suggests a potential additional mechanism for cangrelor's in vivo efficacy beyond its anti-aggregatory effects.
Further research is needed to determine if other P2Y12 inhibitors share this effect on coated-platelet production.